Search Results - "García Pérez, M.J."

PB1945 EXPERIENCE OF THE ANDALUSIAN CHRONIC MYELOID LEUKEMIA GROUP (GALMC) IN THE DISCONTINUATION OF THE TYROSINE KINASE INHIBITOR TREATMENT OUTSIDE OF CLINICAL TRIALS by Alarcón‐Payer, C., Puerta Puerta, J.M., Jiménez Morales, A., Ramírez Sánchez, M.J., Montero Cuadrado, M.I., Mata Vázquez, M.I., Ferrer Chaves, C., Anguita Arance, M., Vera Goñi, J.A., García Pérez, M.J., Mellado Gázquez, Á., Moatassim de la Torre, Y., Hermosín Ramos, L., Jurado Chacón, M., López Garrido, P.

“…Background: Currently one of the most burning issues regarding the specific treatment of Chronic Myeloid Leukemia (CML) with Interleukin‐2‐inducible T‐cell…”
Get full text

PB1898 SAFETY AND EFFECTIVENESS OF CHLORAMBUCIL‐OBINUTUZUMAB IN THE FRONT LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: REAL‐LIFE DATA FROM ANDALUSIAN LYMPHOID NEOPLASM GROUP (GRANEL) by Puerta Puerta, J.M., Martín Palanco, V., Badiola, J., Fernández de la Mata, M., Ortiz Pareja, M., Martínez Quesada, M.J., Rodríguez Fernández, A., De la Cruz Vicente, F., Ferrer Chaves, C., Lorente de Uña, S., Moya Rodríguez, R., García Pérez, M.J., García Martín, P., García Cabrera, I.M., Berruezo Salazar, M.J., Fernández Jiménez, D., Ríos Herranz, E.

“…Background: The Chlorambucil‐Obinutuzumab (CI‐O) is a therapeutic regimen for unfit patients with chronic lymphocytic leukemia (CLL), whether due to old age or…”
Get full text